 Clovis Oncology Inc. CLVS , Financial and Denali Therapeutics Inc. DNLI , Financial are among the most likely biotechs to be acquired, according to industry publications. Denali, by far, would be the most expensive of the pair with a market cap of 6.4 billion, while Clovis is far more digestible with a market value of only 567 million. 